New study aims to spare thousands of breast cancer patients from unnecessary chemo
NCT ID NCT07379918
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at a genomic test called EndoPredict that analyzes tumor genes to predict the risk of breast cancer returning. The goal is to see if women with a low-risk score can safely skip chemotherapy and only take hormone therapy. Researchers will follow 1,000 patients for 10 years to track relapse and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EndoPredict genomic test
- What this could lead to
- If successful, this could help doctors safely skip chemotherapy for many women with early breast cancer, reducing side effects without increasing relapse risk.
- What could go wrong
- This is an observational study, not a treatment trial. It will gather real-world data but won't directly prove that skipping chemotherapy is safe for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER PROGNOSTIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Saint-Louis
RECRUITINGParis, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Could gentle fascia release restore shoulder mobility after breast cancer surgery?
- Could ring fit adventures fight depression in breast cancer survivors?
- Heating up tumors: could thermal therapy boost immune attack on breast cancer?
- Could a diabetes drug slow breast cancer growth?
- Could thousands of women skip hormone therapy after breast cancer?